Αρχική World News FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection World News FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection Από Ogkologos - 7 Φεβρουαρίου, 2025 945 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-67T study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR 38% of Recurrent Breast Cancers Have a Different HER2 Status than... 25 Μαΐου, 2021 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... 5 Αυγούστου, 2021 Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors 25 Ιουνίου, 2020 Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... 30 Σεπτεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan Checking in on our Mental Health Cancer Survivors Face High Rates of Housing Insecurity EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib